<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2020-08-19</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2253</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NOTES FROM PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ ОПЫТ</subject></subj-group></article-categories><title-group><article-title>In the Refractory Hypertension “Labyrinth”. Focus on Primary Hyperaldosteronism</article-title><trans-title-group xml:lang="ru"><trans-title>В «лабиринте» рефрактерной артериальной гипертензии. Фокус на первичный гиперальдостеронизм</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыганкова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsygankova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цыганкова Оксана Васильевна – доктор медицинских наук, профессор, кафедра неотложной терапии с эндокринологией и профпатологией, факультет повышения квалификации и профессиональной переподготовки врачей, Новосибирский ГМУ; старший научный сотрудник, лаборатория клинических, биохимических и гормональных исследований терапевтических заболеваний, НИИ ТПМ – филиал ИЦиГ СО РАН</p><p>630089, Новосибирск, ул. Б. Богаткова, 175/1, </p><p>630091, Новосибирск, ул. Красный проспект, 52 </p></bio><bio xml:lang="en"><p>Oksana V. Tsygankova – MD, PhD, Professor, Chair of Emergency Therapy with Endocrinology and Occupational Pathology, Novosibirsk State Medical University; Senior Researcher, Laboratory for Clinical, Biochemical and Hormonal Research of Therapeutic Diseases, Institute of Internal and Preventive Medicine – Branch of Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science</p><p>B. Bogatkova ul. 175/1, Novosibirsk, 630089, </p><p>Krasny prospect 52, Novosibirsk, 630091 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Батлук</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Batluk</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Батлук Татьяна Ивановна – аспирант</p><p>630089, Новосибирск, ул. Б. Богаткова, 175/1 </p></bio><bio xml:lang="en"><p>Tatiana I. Batluk – Postgraduate Student</p><p>B. Bogatkova ul. 175/1, Novosibirsk, 630089</p></bio><email xlink:type="simple">novagirl@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Латынцева</surname><given-names>Л. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Latyntseva</surname><given-names>L. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Латынцева Людмила Дмитриевна – кандидат медицинских наук, заведующая терапевтическим отделением, старший научный сотрудник, лаборатория неотложной кардиологии</p><p>630089, Новосибирск, ул. Б. Богаткова, 175/1 </p></bio><bio xml:lang="en"><p>Lyudmila D. Latyntseva – MD, PhD, Head of Therapeutic Department, Senior Researcher, Laboratory of Emergency Cardiology</p><p>B. Bogatkova ul. 175/1, Novosibirsk, 630089</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахмерова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmerova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ахмерова Елена Викторовна – кандидат медицинских наук, заведующая Городским эндокринологическим центром</p><p>630078, Новосибирск, ул. 1-й пер. Пархоменко, 32 </p></bio><bio xml:lang="en"><p>Elena V. Akhmerova – MD, PhD, Head of City Endocrinology Center</p><p>Parhomenko pervyj per. 32 Novosibirsk, 630078 </p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахмеджанов</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmedzhanov</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ахмеджанов Надир Мигдатович – кандидат медицинских наук, ведущий научный сотрудник, отдел профилактики метаболических нарушений</p><p>101990 Москва, Петроверигский пер., 10 </p></bio><bio xml:lang="en"><p>Nadir M. Akhmedzhanov – MD, PhD, Leading Researcher, Department of Metabolic Disorders Prevention</p><p>Petroverigsky per. 10, Moscow, 101990 </p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт терапии и профилактической медицины – филиал Института цитологии и генетики Сибирского отделения Российской академии наук;&#13;
Новосибирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Internal and Preventive Medicine – Branch of Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science;&#13;
Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт терапии и профилактической медицины – филиал Института цитологии и генетики Сибирского отделения Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Internal and Preventive Medicine – Branch of Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Городская клиническая поликлиника №16 (Новосибирск)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Polyclinic №16</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Национальный медицинский научно-исследовательский центр терапии и профилактической медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>01</day><month>09</month><year>2020</year></pub-date><volume>16</volume><issue>4</issue><fpage>557</fpage><lpage>563</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Tsygankova O.V., Batluk T.I., Latyntseva L.D., Akhmerova E.V., Akhmedzhanov N.M., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Цыганкова О.В., Батлук Т.И., Латынцева Л.Д., Ахмерова Е.В., Ахмеджанов Н.М.</copyright-holder><copyright-holder xml:lang="en">Tsygankova O.V., Batluk T.I., Latyntseva L.D., Akhmerova E.V., Akhmedzhanov N.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2253">https://www.rpcardio.online/jour/article/view/2253</self-uri><abstract><p>Primary hyperaldosteronism is an existence of a functional autonomous source with increased aldosterone production (full or partial) in relation to the renin-angiotensin system. Increased production of aldosterone by the adrenal cortex is the most common form of a secondary hypertension despite the low attention of internists to the problem. The success of a treatment and a prognosis of these patients depend on correct choice of screening (aldosterone/renin ratio) and clarifying diagnostic methods. There are clear algorithms for conducting these tests in accordance with Russian and International recommendations in the respective groups of patients. The purpose of this case report is to demonstrate the long way to diagnosis of primary hyperaldosteronism in a young patient with refractory hypertension, right adrenal adenoma, and clinical (convulsions, weakness) and laboratory signs of hypokalemia. It should not only have made the diagnosis easy, but it could have also absolutely justified the surgical tactics. Unfortunately, the final verification of the disease by carrying out a saline test was accomplished 13 years after the debut of hypertension and 10 years after the primary visualization of the adrenal adenoma.</p></abstract><trans-abstract xml:lang="ru"><p>Первичный гиперальдостеронизм – функциональная автономность источника повышенной продукции альдостерона (полная или частичная) по отношению к ренин-ангиотензиновой системе. Несмотря на малую настороженность врачей первичного звена в его выявлении, повышенная продукция альдостерона корой надпочечников является наиболее распространенной формой вторичной артериальной гипертензии (АГ). Успех лечения и прогноз у этих пациентов напрямую зависят от правильного выбора скринингового (альдостерон/рениновое соотношение) и уточняющих диагностических методов, проведение которых, согласно российским и международным рекомендациям, в соответствующих группах риска четко алгоритмизировано. Приведенный клинический случай содержит описание неоправданно пролонгированных этапов диагностического поиска у пациентки молодого возраста с наличием рефрактерной АГ на фоне образования правого надпочечника, клиническими (судороги, слабость) и лабораторными признаками гипокалиемии, что, казалось бы, делает диагноз гиперальдостеронизма очевидным, а хирургическую тактику абсолютно оправданной. Несмотря на это, окончательная верификация заболевания, подтвержденная проведением теста с физиологическим раствором, была осуществлена через 13 лет от дебюта АГ и спустя 10 лет от первичной визуализации аденомы надпочечника.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рефрактерная артериальная гипертензия</kwd><kwd>первичный гиперальдостеронизм</kwd><kwd>аденома надпочечника</kwd><kwd>клинический случай</kwd></kwd-group><kwd-group xml:lang="en"><kwd>refractory hypertension</kwd><kwd>primary hyperaldosteronism</kwd><kwd>adrenal adenoma</kwd><kwd>clinical case</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа частично выполнена по Государственному заданию в рамках бюджетной темы №АААА-А17- 117112850280-2</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Funder J.W., Carey R.M., Mantero F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. DOI:10.1210/jc.2015-4061.</mixed-citation><mixed-citation xml:lang="en">Funder J.W., Carey R.M., Mantero F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. DOI:10.1210/jc.2015-4061.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1-10. DOI:10.1210/jc.2014-3663.</mixed-citation><mixed-citation xml:lang="en">Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1-10. DOI:10.1210/jc.2014-3663.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826-33. DOI:10.1210/jc.2013-2805.</mixed-citation><mixed-citation xml:lang="en">Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826-33. DOI:10.1210/jc.2013-2805.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Надеева Р.А., Камалиева Г.Р., Ягфарова Р.Р. Первичный гиперальдостеронизм в структуре артериальной гипертонии: актуальность проблемы. Вестник Современной Клинической Медицины. 2015;8(6):98-102. DOI:10.20969/vskm.2015.8(6).98-102.</mixed-citation><mixed-citation xml:lang="en">Nadeeva R.A., Kamasheva G.R., Yagfarova R.R. Primary hyperaldoseronism in the structure of arterial hypertension: actuality of problem. The Bulletin of Contemporary Clinical Medicine. 2015;8(6):98- 102 (In Russ.) DOI:10.20969/vskm.2015.8(6).98-102.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Young W.F. Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-48. DOI:10.1111/joim.12831.</mixed-citation><mixed-citation xml:lang="en">Young W.F. Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-48. DOI:10.1111/joim.12831.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. DOI:10.1016/j.jacc.2005.01.015.</mixed-citation><mixed-citation xml:lang="en">Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. DOI:10.1016/j.jacc.2005.01.015.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Monticone S., D'Ascenzo F., Moretti C., et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. DOI:10.1016/S2213-8587(17)30319-4.</mixed-citation><mixed-citation xml:lang="en">Monticone S., D'Ascenzo F., Moretti C., et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. DOI:10.1016/S2213-8587(17)30319-4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Prada E.T.A., Burrello J., Reincke M., Williams T.A. Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. Hypertension. 2017;70:875-81. DOI:10.1161/HYPERTENSIONAHA.117.10111.</mixed-citation><mixed-citation xml:lang="en">Prada E.T.A., Burrello J., Reincke M., Williams T.A. Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. Hypertension. 2017;70:875-81. DOI:10.1161/HYPERTENSIONAHA.117.10111.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический Архив. 2018;9:115-22. DOI:10.26442/terarkh2018909115-122.</mixed-citation><mixed-citation xml:lang="en">Chikladze N.M., Favorova O.O., Chazova I.E. Family hyperaldosteronism type I: a clinical case and review of literature. Ter Arkhiv. 2018;9:115-22 (In Russ.) DOI:10.26442/terarkh2018909115-122.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Omata K., Satoh F., Morimoto R., et al. Cellular and Genetic Causes of Idiopathic Hyperaldosteronism. Hypertension. 2018;72(4):874-80. DOI:10.1161/HYPERTENSIONAHA.118.11086.</mixed-citation><mixed-citation xml:lang="en">Omata K., Satoh F., Morimoto R., et al. Cellular and Genetic Causes of Idiopathic Hyperaldosteronism. Hypertension. 2018;72(4):874-80. DOI:10.1161/HYPERTENSIONAHA.118.11086.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Liao C.W., Lin Y.T., Wu X.M., et al.; TAIPAI Study Group. The relation among aldosterone, galectin3, and myocardial fibrosis: a prospective clinical pilot follow-up study. J Investig Med. 2016;64(6):1109-13. DOI:10.1136/jim-2015-000014.</mixed-citation><mixed-citation xml:lang="en">Liao C.W., Lin Y.T., Wu X.M., et al.; TAIPAI Study Group. The relation among aldosterone, galectin3, and myocardial fibrosis: a prospective clinical pilot follow-up study. J Investig Med. 2016;64(6):1109-13. DOI:10.1136/jim-2015-000014.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lee H.H., Hung C.S., Wu X.M., et al.; Taipai Study Group. Myocardial ultrasound tissue characterization of patients with primary aldosteronism. Ultrasound Med Biol. 2013;39(1):54-61. DOI:10.1016/j.ultrasmedbio.2012.08.023.</mixed-citation><mixed-citation xml:lang="en">Lee H.H., Hung C.S., Wu X.M., et al.; Taipai Study Group. Myocardial ultrasound tissue characterization of patients with primary aldosteronism. Ultrasound Med Biol. 2013;39(1):54-61. DOI:10.1016/j.ultrasmedbio.2012.08.023.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Grytaas M.A., Sellevåg K., Thordarson H.B., et al. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism. Endocr Connect. 2018;7(3):413-24. DOI:10.1530/EC18-0039.</mixed-citation><mixed-citation xml:lang="en">Grytaas M.A., Sellevåg K., Thordarson H.B., et al. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism. Endocr Connect. 2018;7(3):413-24. DOI:10.1530/EC18-0039.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Цыганкова О.В., Калинина Е.М., Латынцева Л.Д., Воевода М.И. Успешный опыт коррекции рефрактерной артериальной гипертонии и морбидного ожирения у пациента с синдромом обструктивного апноэ сна тяжелой степени. Российский Кардиологический Журнал. 2018;(5):74-80. DOI:10.15829/1560-4071-2018-5-74-80.</mixed-citation><mixed-citation xml:lang="en">Tsygankova O.V., Kalinina E..M, Latyntseva L.D., Voevoda M.I. Successful correction of refractory arterial hypertension and morbid obesity in patient with severe obstructive apnea syndrome. Russian Journal of Cardiology. 2018;(5):74-80 (In Russ.) DOI:10.15829/1560-4071-2018-5-74-80.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dudenbostel T., Calhoun D.A. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2011;26(5):281-7. DOI:10.1038/jhh.2011.4.</mixed-citation><mixed-citation xml:lang="en">Dudenbostel T., Calhoun D.A. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2011;26(5):281-7. DOI:10.1038/jhh.2011.4.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Calhoun D.A., Nishizaka M.K., Zaman M.A., Harding S.M. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125(1):112-7. DOI:10.1378/chest.125.1.112.</mixed-citation><mixed-citation xml:lang="en">Calhoun D.A., Nishizaka M.K., Zaman M.A., Harding S.M. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125(1):112-7. DOI:10.1378/chest.125.1.112.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzaga C.C., Gaddam K.K., Ahmed M.I., et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363-8. DOI:10.1097/01.hjh.0000379812.66839.11.</mixed-citation><mixed-citation xml:lang="en">Gonzaga C.C., Gaddam K.K., Ahmed M.I., et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363-8. DOI:10.1097/01.hjh.0000379812.66839.11.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Di Murro A., Petramala L., Cotesta D., et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System. 2010;11(3):165-72. DOI:10.1177/1470320310366581.</mixed-citation><mixed-citation xml:lang="en">Di Murro A., Petramala L., Cotesta D., et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System. 2010;11(3):165-72. DOI:10.1177/1470320310366581.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С. Эволюционные стадии низкорениновой артериальной гипертонии. Рациональная Фармакотерапия в Кардиологии. 2010;6(1):68-72. DOI:10.20996/1819-6446-2010-6-1-68-72.</mixed-citation><mixed-citation xml:lang="en">Akhadov S.V., Ruzbanova G.R., Molchanovа G.S. Evolution stages of low renin hypertension. Rational Pharmacotherapy in Cardiology. 2010;6(1):68-72 (In Russ.) DOI:10.20996/1819-6446-2010-6-1-68-72.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hanon O., Boully C., Caillard L., et al. Treatment of hypertensive patients with diabetes and microalbuminuria with combination indapamide SR/amlodipine: retrospective analysis of NESTOR. Am J Hypertens. 2015;28:1064-71. DOI:10.1093/ajh/hpu297.</mixed-citation><mixed-citation xml:lang="en">Hanon O., Boully C., Caillard L., et al. Treatment of hypertensive patients with diabetes and microalbuminuria with combination indapamide SR/amlodipine: retrospective analysis of NESTOR. Am J Hypertens. 2015;28:1064-71. DOI:10.1093/ajh/hpu297.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Маркель А.Л. Генетика и патофизиология низкорениновой артериальной гипертонии. Вавиловский Журнал Генетики и Селекции. 2018;22(8):1000-8. DOI:10.18699/vj18.443.</mixed-citation><mixed-citation xml:lang="en">Markel A.L. Genetics and pathophysiology of low-renin arterial hypertension. Vavilov Journal of Genetics and Breeding. 2018;22(8):1000-8 (In Russ.) DOI:10.18699/vj18.443.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Мельниченко Г.А., Платонова Н.М., Бельцевич Д.Г. и др. Первичный гиперальдостеронизм: диагностика и лечение. Новый взгляд на проблему. По материалам Проекта клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма. Consilium Medicum. 2017;19(4):75-85. DOI:10.26442/2075-1753_19.4.75-85.</mixed-citation><mixed-citation xml:lang="en">Melnichenko G.A., Platonova N.M., Beltsevich D.G., et al. Primary hyperaldosteronism: diagnosis and treatment. A new look at the problem. According to the materials of the Russian Association of Endocrinologists clinical guidelines for primary hyperaldosteronism diagnosis and treatment. Consilium Medicum. 2017;19(4):75-85 (In Russ.) DOI:10.26442/2075-1753_19.4.75-85.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Williams T.A., Reincke M. Management of endocrine disease: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19- R29. DOI:10.1530/EJE-17-0990.</mixed-citation><mixed-citation xml:lang="en">Williams T.A., Reincke M. Management of endocrine disease: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19- R29. DOI:10.1530/EJE-17-0990.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Mulatero P., Stowasser M., Loh K.C., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism. 2004;89(3):1045-50. DOI:10.1210/jc.2003-031337.</mixed-citation><mixed-citation xml:lang="en">Mulatero P., Stowasser M., Loh K.C., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism. 2004;89(3):1045-50. DOI:10.1210/jc.2003-031337.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., ред. Инциденталома надпочечников (диагностика и дифференциальная диагностика). Клинические рекомендации для врачей первичного звена. М.: ФГБУ ЭНЦ; 2015.</mixed-citation><mixed-citation xml:lang="en">Dedov I.I., Melnichenko G.A., eds. Incidentaloma nadpochechnikov (diagnostika i differencialnaya diagnostika). Metodicheskie rekomendacii dlya vrachej pervichnogo zvena. M.: FGBU ENC; 2015 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Young W.F., Stanson A.W., Thompson G.B., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227-35. DOI:10.1016/j.surg.2004.06.051.</mixed-citation><mixed-citation xml:lang="en">Young W.F., Stanson A.W., Thompson G.B., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227-35. DOI:10.1016/j.surg.2004.06.051.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Nwariaku F.E., Miller B.S., Auchus R., et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg. 2006;141(5):497-502. DOI:10.1001/archsurg.141.5.497.</mixed-citation><mixed-citation xml:lang="en">Nwariaku F.E., Miller B.S., Auchus R., et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg. 2006;141(5):497-502. DOI:10.1001/archsurg.141.5.497.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Цыганкова О.В., Худякова А.Д., Латынцева Л.Д., Ложкина Н.Г. Сердечно-сосудистый континуум: от факторов риска до систолической сердечной недостаточности. Атеросклероз. 2017;13(4):42-6. DOI:10.15372/ATER20170407.</mixed-citation><mixed-citation xml:lang="en">Tsygankova O.V., Khudyakova A.D., Latyntseva L.D., Lozhkina N.G. Cardiovascular continuum: from risk factors to the systolyc heart failure (the clinical case). Atherosclerosis. 2017;13(4):42-6 (In Russ.) DOI:10.15372/ATER20170407.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
